Companies: GTX   

There is some real momentum to Genetix’s cell biology business. New products aimed at providing shortcuts for drug discovery powered sales to more than £10 million in the half-year to the end of June. That compares with £6 million in the comparable period. Profits jumped by a similar amount to £1 million, though the gain was largely down to a first-time contribution from recent acquisition Applied Imaging. Adjusted earnings emerged at 1.41p, up 11 per cent. The company has £11.5 million in the bank, equivalent to a quarter of the current market capitalisation.

Although 10p down on the 75.5p at which I recommended them in March, the shares are well worth holding. Genetix is in the right place at the right time.

Genetix Group	AIM	£29.79m	41.50p	-1.00p
Click here for interactive charting
Other company articles:
New products help Genetix			07/08/2008
Maiden payout from Genetix			04/03/2008
Cell biology boosts Genetix			17/01/2008
Genetix sees big sales growth			23/08/2007
Acquisition lifts Genetix sales			23/08/2007